smartbax
Key Facts
| Invested since | 2022 |
| Based in | Munich |
About the company
smartbax is developing a new generation of antibiotics to address the increasing spread of multi-drug resistant bacteria. Their team of experts is advancing a complementary pipeline of small molecules against novel bacterial targets and with innovative modes of action to prevent resistance. Their lead program is a new inhibitor of lipopolysaccharide synthesis in Gram-negative bacteria. Moreover, the company specializes in the tailored activation of enzymatic pathways that trigger bacterial self-digestion, as this approach is particularly promising in the context of difficult-to-treat biofilms. Two activators are in development, targeting both Gram-positive bacteria and Gram-negative bacteria individually. Knowing that preventing a resistance crisis tomorrow means taking action today, smartbax was founded in 2021 as a spin-off of the Technical University Munich (TUM) with the aim of making innovative research applicable in creating novel antibiotics that add true value for patients worldwide.
Do you want to
know more about this company?
smartbax in the news
zum Artikel
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
zum Artikel
smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics
More startups from Life Sciences
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill …
PEPperPRINT produces customized ultra-high density peptide microarrays and uses individualized peptide libraries for drug development, antibody characterization, and protein biomarker discovery.
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. …
Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach …
HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the …
PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) – based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.
The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses …
Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible …
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary …
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …
